CJC-1295 No DAC + Ipamorelin is a synergistic peptide combination developed for advanced endocrine and growth hormone pathway research. By pairing a short-acting growth hormone–releasing hormone (GHRH) analogue with a selective ghrelin receptor agonist, this blend allows researchers to examine pulsatile growth hormone signalling through complementary but distinct mechanisms.
This dual-pathway interaction has made CJC-1295 No DAC + Ipamorelin a widely used model in studies focused on growth hormone release dynamics, receptor sensitivity, and downstream metabolic signalling.
Key Features
• Research-grade, high-purity peptide blend • Dual-pathway growth hormone axis activation model • CJC-1295 No DAC supports endogenous GHRH signalling • Ipamorelin selectively targets the ghrelin (GHS-R) receptor • Manufactured under cGMP conditions • Batch-specific Certificate of Analysis (COA) supplied • Stable when stored under recommended conditions
Research Applications
• Growth hormone secretion and pulsatility studies • GH/IGF-1 axis signalling research • Endocrine pathway interaction analysis • Metabolic and recovery-related mechanism investigation • Comparative analysis versus single-compound peptides
CJC-1295 No DAC + Ipamorelin provides researchers with a valuable tool for examining coordinated growth hormone regulation and the interaction between GHRH- and ghrelin-mediated signalling pathways.
For laboratory research use only. Not for human consumption.
